[1] |
LI Wei, ZHANG Shanling, TAO Yingjie, WANG Xudong.
Research status and progress of mechanism of T cell immune metabolism and its application combined with immune checkpoint inhibitor
[J]. China Oncology, 2021, 31(7): 640-646.
|
[2] |
XIAO Feng , XIAO Jingwen , SHAO Jianguo , CHEN Liyan , GU Chunyan .
The expression of programmed death 1 in tumor-infiltrating lymphocytes of hepatocellular carcinoma and its correlation with prognosis
[J]. China Oncology, 2021, 31(5): 419-427.
|
[3] |
YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying .
Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(3): 203-211.
|
[4] |
ZHAO Haiyun, WU Xiaohua.
Research progress of immunotherapy in ovarian cancer
[J]. China Oncology, 2020, 30(7): 538-545.
|
[5] |
YANG Xiaoling, SI Lu, MAO Lili, WANG Xuan, CUI Chuanliang, CHI Zhihong, SHENG Xi’nan, GUO Jun.
Adverse events of pembrolizumab in patients with advanced melanoma and correlation analysis
[J]. China Oncology, 2020, 30(5): 362-368.
|
[6] |
WANG Ping, YANG Wenxiu, ZHOU Jie, FENG Jianglong, LIN Chaoqun.
The correlation of NF-κB/p65, PD-1 and PD-L1 expressions and their clinical significance in diffuse large B-cell lymphoma
[J]. China Oncology, 2020, 30(5): 375-382.
|
[7] |
MENG Qiuhua, TIAN Jing, QIN Yan, MENG Qiuxiao, DONG Min.
The mechanism of protein tyrosine phosphatase receptor type delta affecting expression of PD-L1 in hepatocellular carcinoma via STAT3 pathway
[J]. China Oncology, 2020, 30(4): 261-267.
|
[8] |
ZHU Xiaodong, CHEN Siyuan.
Combination therapy of immune checkpoint inhibitors: from rationale to practice
[J]. China Oncology, 2020, 30(12): 969-976.
|
[9] |
WANG Jie .
Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer
[J]. China Oncology, 2020, 30(10): 744-749.
|
[10] |
FANG Yujia, ZHOU Juan, SU Chunxia.
Immune microenvironment for liver metastasis of non-small cell lung cancer and future intervention strategies
[J]. China Oncology, 2020, 30(10): 750-758.
|
[11] |
LI Yuan.
Personalized immunotherapy for lung cancer under the guidance of pathology
[J]. China Oncology, 2020, 30(10): 770-776.
|
[12] |
YANG Lingge, WANG Chunmeng.
Drug therapy for alveolar soft part sarcoma: current status and progress
[J]. China Oncology, 2019, 29(9): 746-752.
|
[13] |
ZHAO Haiyun, JI Peng, LI Xiaoguang, et al.
Research progress of biomarkers associated with efficacy of immune checkpoint blockade
[J]. China Oncology, 2018, 28(11): 852-857.
|
[14] |
GUO Ye.
The immunotherapy for head and neck cancer
[J]. China Oncology, 2017, 27(6): 459-462.
|
[15] |
CAO Dalong, YE Dingwei.
Advances in immunotherapy for metastatic renal cancer
[J]. China Oncology, 2017, 27(10): 829-832.
|